Teva Pharmaceutical Industries (TEVA) Capital Expenditures (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Capital Expenditures came in at $104.0 million in Q2 2026, up 8.33% YoY from $96.0 million in Q2 2025, and down 38.1% on a QoQ basis from $168.0 million in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Capital Expenditures (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Capital Expenditures data on file, last reported at $104.0 million in Q2 2026.
- Quarterly Capital Expenditures rose 8.33% year-over-year to $104.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $550.0 million (up 10.0% YoY) and the FY2025 annual result came in at $501.0 million, up 0.6% from the prior year.
- Capital Expenditures slipped to $104.0 million in Q2 2026, from $168.0 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $168.0 million in Q1 2026 to a low of $96.0 million in Q2 2025.
- A 5-year average of $130.3 million and a median of $128.0 million in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2024 — Capital Expenditures fell 18.49% — and 2026, when it soared 32.28%.
- Tracing TEVA's Capital Expenditures over 5 years: stood at $142.0 million in 2022, then fell by 16.2% to $119.0 million in 2023, then grew by 8.4% to $129.0 million in 2024, then climbed by 10.08% to $142.0 million in 2025, then declined by 26.76% to $104.0 million in 2026.
- The last three Capital Expenditures figures came in at $104.0 million (Q2 2026), $168.0 million (Q1 2026), and $142.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 8.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104.00 Mn |
| Jun 30, 2026 | 104.00 Mn |
| Mar 31, 2026 | 168.00 Mn |
| Mar 31, 2026 | 168.00 Mn |
| Dec 31, 2025 | 142.00 Mn |
| Dec 31, 2025 | 142.00 Mn |
| Sep 30, 2025 | 136.00 Mn |
| Sep 30, 2025 | 136.00 Mn |
| Jun 30, 2025 | 96.00 Mn |
| Jun 30, 2025 | 96.00 Mn |
| Mar 31, 2025 | 127.00 Mn |
| Mar 31, 2025 | 127.00 Mn |
| Dec 31, 2024 | 129.00 Mn |
| Dec 31, 2024 | 129.00 Mn |
| Sep 30, 2024 | 148.00 Mn |
| Sep 30, 2024 | 148.00 Mn |
| Jun 30, 2024 | 97.00 Mn |
| Jun 30, 2024 | 97.00 Mn |
| Mar 31, 2024 | 124.00 Mn |
| Mar 31, 2024 | 124.00 Mn |